Show simple item record

dc.contributor.authorFord, Nathan
dc.contributor.authorCalmy, Alexandra
dc.contributor.authorMofenson, Lynne
dc.date.accessioned2012-12-11T22:57:27Z
dc.date.available2012-12-11T22:57:27Z
dc.date.issued2011-11-28
dc.identifier.citationAIDS 2011; 25(18):2301-4en_GB
dc.identifier.issn1473-5571
dc.identifier.pmid21918421
dc.identifier.doi10.1097/QAD.0b013e32834cdb71
dc.identifier.urihttp://hdl.handle.net/10144/255366
dc.descriptionArticle approval pending
dc.description.abstractEvidence of the risk of birth defects with efavirenz use is limited. We updated a meta-analysis of birth defects in infants with first trimester efavirenz exposure up to July 2011. In 21 studies, there were 39 defects among live births in 1437 women receiving first trimester efavirenz [2.0%, 95% confidence interval (CI) 0.82-3.18]. The relative risk of defects comparing women on efavirenz-based (1290 live births) and nonefavirenz-based regimens (8122 live births) was 0.85 (95% CI 0.61-1.20). One neural tube defect was observed (myelomeningocele), giving an incidence of 0.07% (95% CI 0.002-0.39).
dc.language.isoenen
dc.publisherLippincott Williams & Wilkinsen_GB
dc.relation.urlhttp://journals.lww.com/aidsonline/Abstract/2011/11280/Safety_of_efavirenz_in_the_first_trimester_of.13.aspxen_GB
dc.rightsPublished by Wolters Kluwer Lippincott Williams & Wilkins - Archived on this site by kind permission Wolters Kluweren_GB
dc.subject.meshAbnormalities, Drug-Induceden_GB
dc.subject.meshAnti-HIV Agentsen_GB
dc.subject.meshBenzoxazinesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIncidenceen_GB
dc.subject.meshNeural Tube Defectsen_GB
dc.subject.meshPregnancyen_GB
dc.subject.meshPregnancy Complications, Infectiousen_GB
dc.subject.meshPregnancy Outcomeen_GB
dc.subject.meshPregnancy Trimester, Firsten_GB
dc.subject.meshRisk Factorsen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleSafety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisen
dc.typeArticleen
dc.contributor.departmentCentre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Médecins Sans Frontières, Geneva, Switzerland; Geneva University Hospital, HIV Unit, Service of Infectious Diseases, Geneva, Switzerland; Pediatric, Adolescent and Maternal AIDS Branch, Center for Research for Mothers and Children, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USAen_GB
dc.identifier.journalAIDS (London, England)en_GB
refterms.dateFOA2019-03-04T10:06:34Z
html.description.abstractEvidence of the risk of birth defects with efavirenz use is limited. We updated a meta-analysis of birth defects in infants with first trimester efavirenz exposure up to July 2011. In 21 studies, there were 39 defects among live births in 1437 women receiving first trimester efavirenz [2.0%, 95% confidence interval (CI) 0.82-3.18]. The relative risk of defects comparing women on efavirenz-based (1290 live births) and nonefavirenz-based regimens (8122 live births) was 0.85 (95% CI 0.61-1.20). One neural tube defect was observed (myelomeningocele), giving an incidence of 0.07% (95% CI 0.002-0.39).


Files in this item

Thumbnail
Name:
Ford Safety of efavirenz in the ...
Size:
168.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record